Scarica l'app Stockscreener
2.07
1.90%
-0.04
Precedente Chiudi:
$2.11
Aprire:
$2.18
Volume 24 ore:
116.53K
Relative Volume:
0.43
Capitalizzazione di mercato:
$18.61M
Reddito:
$14.58M
Utile/perdita netta:
$-12.57M
Rapporto P/E:
-0.3644
EPS:
-5.68
Flusso di cassa netto:
$-13.07M
1 W Prestazione:
+0.00%
1M Prestazione:
-17.86%
6M Prestazione:
-2.82%
1 anno Prestazione:
-53.48%
Intervallo 1D:
$2.04
$2.1834
Intervallo di 1 settimana:
$2.04
$2.28
Portata 52W:
$1.98
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Nome
Vivos Therapeutics Inc
Settore
Industria
Telefono
(866)908-4867
Indirizzo
7921 SOUTHPARK PLAZA,, LITTLETON
Confronta VVOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
2.07 | 18.96M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Vivos Therapeutics Inc Borsa (VVOS) Ultime notizie
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Vivos Therapeutics Inc Stock Analysis and ForecastBull Market Opportunities & Use Our Sector Rotation Strategy for Gains - earlytimes.in
What analysts say about Vivos Therapeutics Inc stockPrice Momentum Alerts & What the Pros Are Saying About This Stock - earlytimes.in
Vivos Therapeutics secures $2M note with Avondale - MSN
Vivos Therapeutics Secures $2M Note with Avondale - TipRanks
Vivos Therapeutics, Inc. Enters into a Note Purchase Agreement with Avondale Capital, LLC - marketscreener.com
Can Vivos Therapeutics Inc. stock beat analyst upgradesJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - Newser
Is Vivos Therapeutics Inc. stock a buy for dividend growthEarnings Overview Summary & Low Drawdown Momentum Trade Ideas - Newser
Vivos Therapeutics, Inc. announced that it has received $2.09334 million in funding from Avondale Capital, LP - marketscreener.com
Vivos Therapeutics (NASDAQ:VVOS) Given New $5.50 Price Target at Ascendiant Capital Markets - Defense World
Is Vivos Therapeutics Inc. stock a smart buy before Fed meeting2025 Price Momentum & AI Enhanced Trading Alerts - Newser
VVOS: Ascendiant Capital Maintains Buy Rating, Lowers Price Targ - GuruFocus
Ascendiant Capital Maintains Vivos Therapeutics (VVOS) Buy Recommendation - Nasdaq
Vivos Therapeutics (VVOS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges - MSN
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ... By GuruFocus - Investing.com Canada
Why Vivos Therapeutics Inc. stock remains on buy lists2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2025 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vivos Therapeutics Rides Acquisition Wave To Higher Revenue - Finimize
What is HC Wainwright’s Estimate for VVOS Q3 Earnings? - Defense World
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $5.44 Average Target Price from Analysts - Defense World
Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift - MSN
Published on: 2025-11-20 02:04:52 - newser.com
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 - The Manila Times
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth By Investing.com - Investing.com Nigeria
Vivos Therapeutics signals continued revenue acceleration amid SCN integration and SAMC expansion plans - MSN
Vivos Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Why Vivos Therapeutics Inc. stock appeals to analystsFed Meeting & Technical Confirmation Alerts - newser.com
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth - Investing.com India
What technical charts say about Vivos Therapeutics Inc. stockWeekly Gains Summary & Verified Entry Point Signals - newser.com
[8-K] Vivos Therapeutics, Inc. Reports Material Event | VVOS SEC FilingForm 8-K - Stock Titan
Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition - marketscreener.com
Will Vivos Therapeutics Inc. continue its uptrendTake Profit & Verified Swing Trading Watchlist - newser.com
Vivos Therapeutics (NASDAQ: VVOS) reports 78% third quarter revenue growth - Stock Titan
[10-Q] Vivos Therapeutics, Inc. Quarterly Earnings Report | VVOS SEC FilingForm 10-Q - Stock Titan
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Vivos Therapeutics, Inc. Plans Q3 2025 Financial Results Release and Investor Conference Call - Quiver Quantitative
Vivos Therapeutics (NASDAQ: VVOS) to Release Q3 2025 Results, Host Call Today - Stock Titan
Vivos Therapeutics Inc Azioni (VVOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):